...
【24h】

Opioid efficacy in a C6 glioma cell line stably expressing the human kappa opioid receptor.

机译:阿片样物质在稳定表达人κ阿片受体的C6神经胶质瘤细胞系中的功效。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

A C6 glioma cell line stably transfected with the human kappa opioid receptor (kappaOR) was used to characterize receptor binding and G protein activation via the kappaOR by a comprehensive series of opioid ligands. The ligand-binding affinity for [3H]5alpha,7alpha, 8beta(-)-N-methyl-N-(7-Cl-pyrrolidinyl)-1-oxaspiro(4, 5)dec-8-yl)benzene acetamide (U69593) was similar to that observed in monkey brain membranes and was 10-fold lower in the presence of sodium and GDP. Both peptide and nonpeptide agonists maximally stimulated [35S]GTPgammaS binding. The stimulation of [35S]GTPgammaS binding was blocked by pretreatment of cells with pertussis toxin. Partial stimulation of [35S]GTPgammaS binding via the kappaOR was observed for several ligands that are antagonists at the mu opioid receptor, suggesting an additional mechanism of drug action. The ability of isomers of tifluadom and levallorphan to stimulate [35S]GTPgammaS binding indicates that the chiral carbon of levallorphan, a benzomorphan derivative, imparts a greater degree of stereoselectivity than does the chiral carbon in the benzodiazepine derivative tifluadom. In addition, (-)tifluadom, the less potent isomer of tifluadom, which is also a gamma-aminobutyric acidA receptor agonist, stimulated [35S]GTPgammaS binding. In contrast, d-pentazocine, (+)SKF10047, (+)cyclazocine, and d-ethylketocyclazocine displayed no agonist activity. kappaOR-selective antagonist norbinaltorphimine competitively inhibited the stimulation of [35S]GTPgammaS binding by the active isomers of ethylketocyclazocine, cyclazocine, and nalorphine to the same degree, indicating that all three ligands are eliciting an effect via the kappaOR. The results suggest that these cells express a homogeneous population of kappaOR, and that their [35S]GTPgammaS-binding properties make them an excellent means to assess kappaOR efficacy.
机译:稳定转染了人类κ阿片受体(kappaOR)的C6胶质瘤细胞系用于表征受体的结合以及一系列完整的阿片配体通过kappaOR激活G蛋白。对[3H] 5alpha,7alpha,8beta(-)-N-甲基-N-(7-Cl-吡咯烷基)-1-氧杂螺(4,5)dec-8-基)苯乙酰胺的配体结合亲和力(U69593 )与在猴脑膜中观察到的相似,在存在钠和GDP的情况下降低了10倍。肽和非肽激动剂都可以最大程度地刺激[35S] GTPgammaS结合。百日咳毒素预处理细胞可阻断[35S] GTPgammaS结合的刺激。对于在μ阿片样物质受体上拮抗的几种配体,观察到了通过kappaOR部分刺激[35S] GTPgammaS结合的现象,这提示了药物作用的其他机制。 tifluadom和levallorphan的异构体刺激[35S] GTPgammaS结合的能力表明,与benzodiazepine衍生物tifluadom的手性碳相比,levallorphan的手性碳(苯并吗啡衍生物)具有更大的立体选择性。另外,(-)tifluadom,是一种较低效的tifluadom异构体,也是γ-氨基丁酸A受体激动剂,可刺激[35S] GTPgammaS结合。相反,d-戊唑嗪,(+)SKF10047,(+)环唑嗪和d-乙基酮环唑嗪没有激动剂活性。 kappaOR选择性拮抗剂降冰片碱在相同程度上竞争性地抑制了乙基酮基环偶氮星,环唑嗪和纳洛啡的活性异构体对[35S] GTPgammaS结合的刺激,表明所有三个配体均通过kappaOR引起了效应。结果表明这些细胞表达同质的kappaOR群体,并且它们的[35S] GTPgammaS结合特性使其成为评估kappaOR功效的极佳手段。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号